We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Blood Collection in Patients with Fragile Veins Improved

By LabMedica International staff writers
Posted on 08 Mar 2010
Print article
Image: The Microtainer MAP Microtube for Automated Process for hematology testing (photo courtesy BD Diagnostics).
Image: The Microtainer MAP Microtube for Automated Process for hematology testing (photo courtesy BD Diagnostics).
A new hematology-testing device is designed to improve the safety, accuracy, and turnaround time of capillary blood collection and testing in patients with veins that can be difficult to access, such as infants, children, oncology patients, and the elderly.

BD Diagnostics (Franklin Lakes, NJ, USA), a segment of BD (Becton, Dickinson and Company), announced the launch of BD Microtainer MAP Microtube for Automated Process for hematology testing. The new BD Microtainer MAP product is also the first microtube to be fully compatible with most automated hematology instruments, reducing turnaround time, and costs associated with sample transfer and relabeling.

"Clinical laboratories are focused on preventing specimen identification errors that can lead to misdiagnosis of patients. We at BD are pleased to introduce the BD Microtainer MAP product to address this healthcare issue,” said Tom Polen, president, BD Diagnostics--Preanalytical Systems. "BD is committed to continuing our history of innovation in helping improve patient safety and healthcare worker safety, while enhancing workflow efficiency.”

The BD Microtainer MAP tube is the first low-volume collection system to accommodate standard, full-size patient identification labels, thus reducing the risk of labeling errors. This feature offers a significant improvement over traditional microcollection tubes, which are incompatible with standard labels due to their size. This disparity can lead to dangerous labeling errors that may result in misdiagnosis and incorrect patient treatment.

The preanalytic phase is a critical step in the diagnostic process, with significant impact to patient health, healthcare worker safety, and workflow efficiencies. Historically, low-volume capillary blood collection has increased test result turnaround time due to incompatibility with automated testing instruments and a higher risk of patient identification errors.

The innovative design of the BD Microtainer MAP tube enables automated processing with 81% less blood than venous systems, improving test turnaround time and laboratory efficiency. This is a critical improvement for patients from whom it is difficult to obtain a sufficient blood sample to perform critical diagnostic tests.

BD is a leading global medical technology company that develops, manufactures, and sells medical devices, instrument systems, and reagents. BD is focused on improving drug delivery, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research, discovery and production of new drugs and vaccines.

Related Links:

BD Diagnostics


Gold Member
Pharmacogenetics Panel
VeriDose Core Panel v2.0
Verification Panels for Assay Development & QC
Seroconversion Panels
New
HIV Test
Anti-HIV (1/2) Rapid Test Kit
New
Malaria Test
STANDARD Q Malaria P.f/Pan Ag

Print article

Channels

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Microbiology

view channel
Image: The lab-in-tube assay could improve TB diagnoses in rural or resource-limited areas (Photo courtesy of Kenny Lass/Tulane University)

Handheld Device Delivers Low-Cost TB Results in Less Than One Hour

Tuberculosis (TB) remains the deadliest infectious disease globally, affecting an estimated 10 million people annually. In 2021, about 4.2 million TB cases went undiagnosed or unreported, mainly due to... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.